Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vaccine development targeting lipopolysaccharide structure modification.

Microbes and infection - 1 Jan 2000

Zhao Yun, Arce-Gorvel Vilma, Conde-Álvarez Raquel, Moriyon Ignacio, Gorvel Jean-Pierre

Abstract excerpt

Vaccines are one of the most important methods for preventing infectious disease. Structural modification of lipopolysaccharide (LPS) provides a strategy for the development of live attenuated vaccines, either by altering the immunogenicity or by attenuating virulence of the bacteria. This review summarizes various approaches that utilize LPS mutants as whole-cell vaccines.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial Vaccines
Share to Gram-Negative Bacteria
Share to Lipid A

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lipopolysaccharides

Share to Mutation

Share to O Antigens

Share to Oligosaccharides

Share to Vaccines, Attenuated

Source

Identifiers

PMID: 29233768
DOI: 10.1016/j.micinf.2017.11.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vaccine development targeting lipopolysaccharide structure modification.PMID 29233768Read ↗

Lipopolysaccharide: a tool and target in enterobacterial vaccine development.Semantic proximity Read ↗

Next-generation outer membrane vesicle vaccines against Neisseria meningitidis based on nontoxic LPS mutants.Semantic proximity Read ↗

Targeted lipid A modification of <i>Shigella</i> vaccine strains reduced endotoxicity without compromising immunogenicity or invasivenessSemantic proximity Read ↗

Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.Semantic proximity Read ↗

Adjuvant effects elicited by novel oligosaccharide variants of detoxified meningococcal lipopolysaccharides on Neisseria meningitidis recombinant PorA protein: a comparison in mice.Semantic proximity Read ↗

Synthetic biology-inspired development of live attenuated influenza vaccinesSemantic proximity Read ↗

BECC-engineered live-attenuated Shigella vaccine candidates display reduced endotoxicity with robust immunogenicity in miceSemantic proximity Read ↗

Production of a D-glycero-D-manno-heptosyltransferase mutant of Mannheimia haemolytica displaying a veterinary pathogen specific conserved LPS structure; development and functionality of antibodies to this LPS structure.Semantic proximity Read ↗

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines.Semantic proximity Read ↗

Moraxella catarrhalis bacterium without endotoxin, a potential vaccine candidate.Semantic proximity Read ↗

Lipopolysaccharide engineering in Neisseria meningitidis: structural analysis of different pentaacyl lipid A mutants and comparison of their modified agonist properties.Semantic proximity Read ↗

Structural modifications of outer membrane vesicles to refine them as vaccine delivery vehicles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.